Krystal Biotech Japan KK Launches VYJUVEK Commercially in Japan
I'm PortAI, I can summarize articles.
Krystal Biotech Inc. has announced the commercial launch of VYJUVEK® (beremagene geperpavec) in Japan through its subsidiary, Krystal Biotech Japan KK. This treatment is aimed at addressing dystrophic epidermolysis bullosa.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments